Biopharmaceutical CMO And CRO Market Estimates & Strategy Framework To 2022 - 2030

The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.

Biopharmaceutical CMO And CRO Market Segmentation

Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:

Based on the Source Insights, the market is segmented into Mammalian and Non-mammalian.

• The mammalian segment held the highest market share of more than 55% in 2021 owing to the lack of internal expertise in the industry.
• The segment is greatly benefited from the introduction of novel and enhanced expression systems, improved process monitoring solutions, cell line engineering tools, automated screening methods, and disposable devices.
• These developments have led to more productive and efficient manufacturing of biologics using mammalian cells.

Based on the Service Insights, the market is segmented into Contract Manufacturing and Contract Research.

• The contract research segment is expected to exhibit the fastest CAGR of 7.5% over the forecast period owing to the increasing outsourcing of research activities by biopharmaceutical companies.
• A substantial number of CMOs and opportunistic CMOs present in the space are engaged in providing biopharma entities with plenty of services including end-to-end coverage from cell cultivation to fill/finish services.

Based on the Product Insights, the market is segmented into Biologics and Biosimilars.

• The biologics segment dominated the market with the largest revenue share of over 81% in 2021. This growth is attributed to the high specificity of biologics, complex manufacturing steps, and a higher success rate as compared to other drug molecules.
• Furthermore, several companies are investing in biosimilar development to outperform the safety, efficacy, disposition, or cost of earlier in-class innovator drugs.

Biopharmaceutical CMO And CRO Regional Outlook

• North America
• Europe
• Asia-Pacific
• Latin America
• MEA

Key Companies Profile& Market Share Insights

The market is fragmented in nature due to the presence of a substantial number of developed as well as medium- to small-sized CMOs and CROs. Several market participants are privately held or are a part of private equity firms’ portfolios.

Some prominent players in the Biopharmaceutical CMO And CRO Market include

• BoehringerIngelheim GmbH
• Lonza Group AG
• Inno Biologics SdnBhd
• RentschlerBiopharma SE
• JRS Pharma
• Biomeva GmbH
• ProBioGen AG
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Toyobo Co., Ltd.
• Samsung Biologics

Order a free sample PDF  of the Biopharmaceutical CMO And CRO Market Intelligence Study, published by Grand View Research.